OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Regulating Advanced Therapy Medicinal Products through the Hospital Exemption: An Analysis of Regulatory Approaches in Nine EU Countries
D. Coppens, Helga Gardarsdóttir, Marie L. De Bruin, et al.
Regenerative Medicine (2020) Vol. 15, Iss. 8, pp. 2015-2028
Open Access | Times Cited: 13
D. Coppens, Helga Gardarsdóttir, Marie L. De Bruin, et al.
Regenerative Medicine (2020) Vol. 15, Iss. 8, pp. 2015-2028
Open Access | Times Cited: 13
Showing 13 citing articles:
The Regulatory Challenge of 3D Bioprinting
Tajanka Mladenovska, Peter Choong, Gordon G. Wallace, et al.
Regenerative Medicine (2023) Vol. 18, Iss. 8, pp. 659-674
Open Access | Times Cited: 52
Tajanka Mladenovska, Peter Choong, Gordon G. Wallace, et al.
Regenerative Medicine (2023) Vol. 18, Iss. 8, pp. 659-674
Open Access | Times Cited: 52
Expanding access to CAR T cell therapies through local manufacturing
Magdi Elsallab, Marcela V. Maus
Nature Biotechnology (2023) Vol. 41, Iss. 12, pp. 1698-1708
Closed Access | Times Cited: 30
Magdi Elsallab, Marcela V. Maus
Nature Biotechnology (2023) Vol. 41, Iss. 12, pp. 1698-1708
Closed Access | Times Cited: 30
Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products
Natividad Cuende, Rachele Ciccocioppo, Miguel Forte, et al.
Cytotherapy (2022) Vol. 24, Iss. 7, pp. 686-690
Open Access | Times Cited: 30
Natividad Cuende, Rachele Ciccocioppo, Miguel Forte, et al.
Cytotherapy (2022) Vol. 24, Iss. 7, pp. 686-690
Open Access | Times Cited: 30
Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001
Manel Juan, Julio Delgado, Gonzalo Calvo, et al.
Human Gene Therapy (2021) Vol. 32, Iss. 19-20, pp. 1004-1007
Closed Access | Times Cited: 31
Manel Juan, Julio Delgado, Gonzalo Calvo, et al.
Human Gene Therapy (2021) Vol. 32, Iss. 19-20, pp. 1004-1007
Closed Access | Times Cited: 31
Availability and financing of CAR-T cell therapies: A cross-country comparative analysis
Yulia Litvinova, Sherry Merkur, Sara Allin, et al.
Health Policy (2024) Vol. 149, pp. 105153-105153
Open Access | Times Cited: 3
Yulia Litvinova, Sherry Merkur, Sara Allin, et al.
Health Policy (2024) Vol. 149, pp. 105153-105153
Open Access | Times Cited: 3
Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries
Juan Carlos Rejon‐Parrilla, Jaime Espín, Sarah Garner, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Juan Carlos Rejon‐Parrilla, Jaime Espín, Sarah Garner, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the World Health Organization Global Benchmarking Tool standards
Junnan Shi, Xianwen Chen, Hao Hu, et al.
Cytotherapy (2024) Vol. 26, Iss. 8, pp. 954-966
Closed Access | Times Cited: 2
Junnan Shi, Xianwen Chen, Hao Hu, et al.
Cytotherapy (2024) Vol. 26, Iss. 8, pp. 954-966
Closed Access | Times Cited: 2
Access to medicines for rare diseases: A European regulatory roadmap for academia
Noa Rosenberg, Sibren van den Berg, Nina N. Stolwijk, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Noa Rosenberg, Sibren van den Berg, Nina N. Stolwijk, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Polish regulatory system regarding ATMP hospital exemptions
Jan Pachocki, Frances Verter
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Jan Pachocki, Frances Verter
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Analysis of global practices in CAR-T cell production organization and an example of implementation at the Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology
E. A. Badrin, Michael Maschan, Dmitry Pershin, et al.
Annals of the Russian academy of medical sciences (2024) Vol. 79, Iss. 6, pp. 507-514
Closed Access | Times Cited: 1
E. A. Badrin, Michael Maschan, Dmitry Pershin, et al.
Annals of the Russian academy of medical sciences (2024) Vol. 79, Iss. 6, pp. 507-514
Closed Access | Times Cited: 1
Institutional and Infrastructure Challenges for Hospitals Producing Advanced Therapies in the Uk: The Concept of ‘Point-Of-Care Manufacturing Readiness’
Edison Bicudo, Irina Brass
Regenerative Medicine (2022) Vol. 17, Iss. 10, pp. 719-737
Open Access | Times Cited: 4
Edison Bicudo, Irina Brass
Regenerative Medicine (2022) Vol. 17, Iss. 10, pp. 719-737
Open Access | Times Cited: 4
Clinical research and drug regulation in the challenging times of individualized therapies: A pivotal role of clinical pharmacology
Antonio Gómez‐Outes, Aránzazu Sancho‐López, Antonio J. Carcas, et al.
Pharmacological Research (2023) Vol. 199, pp. 107045-107045
Open Access | Times Cited: 2
Antonio Gómez‐Outes, Aránzazu Sancho‐López, Antonio J. Carcas, et al.
Pharmacological Research (2023) Vol. 199, pp. 107045-107045
Open Access | Times Cited: 2
Development, market authorization and market access of gene and cell-based therapies
Renske Maria Tariro ten Ham
(2021)
Open Access
Renske Maria Tariro ten Ham
(2021)
Open Access
